Mitoxantrone targets the ATP-binding site of FAK, binds the FAK kinase domain and decreases FAK, Pyk-2, c-Src, and IGF-1R in vitro kinase activities.

Focal Adhesion Kinase (FAK) is a non-receptor kinase that is overexpressed in many types of tumors and plays a key role in cell adhesion, spreading, motility, proliferation, invasion, angiogenesis, and survival. Recently, FAK has been proposed as a target for cancer therapy, and we performed computer modeling and screening of the National Cancer Institute (NCI) small molecule compounds database to target the ATP-binding site of FAK, K454. More than 140,000 small molecule compounds were docked into the crystal structure of the kinase domain of FAK in 100 different orientations using DOCK5.1 that identified small molecule compounds, targeting the K454 site, called A-compounds. To find the therapeutic efficacy of these compounds, we examined the effect of twenty small molecule compounds on cell viability by MTT assays in different cancer cell lines. One compound, A18 (1,4-bis(diethylamino)-5,8- dihydroxy anthraquinon) was a mitoxantrone derivative and significantly decreased viability in most of the cells comparable to the to the level of FAK kinase inhibitors TAE-226 (Novartis, Inc) and PF-573,228 (Pfizer). The A18 compound specifically blocked autophosphorylation of FAK like TAE-226 and PF-228. ForteBio Octet Binding assay demonstrated that mitoxantrone (1,4-dihydroxy- 5,8-bis[2-(2-hydroxyethylamino) ethylamino] anthracene-9,10-dione directly binds the FAK-kinase domain. In addition, mitoxantrone significantly decreased the viability of breast cancer cells in a dose-dependent manner and inhibited the kinase activity of FAK and Y56/577 FAK phosphorylation at 10-20 μM. Mitoxantrone did not affect phosphorylation of EGFR, but decreased Pyk-2, c-Src, and IGF-1R kinase activities. The data demonstrate that mitoxantrone decreases cancer viability, binds FAK-Kinase domain, inhibits its kinase activity, and also inhibits in vitro kinase activities of Pyk-2 and IGF-1R. Thus, this novel function of the mitoxantrone drug can be critical for future development of anti-cancer agents and FAK-targeted therapy research.

[1]  Ann Y Park,et al.  Role of kinase-independent and -dependent functions of FAK in endothelial cell survival and barrier function during embryonic development , 2010, The Journal of cell biology.

[2]  G. Mcmahon,et al.  PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments , 2010, Cancer biology & therapy.

[3]  V. Golubovskaya,et al.  Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell lines , 2009, Molecular carcinogenesis.

[4]  A. Magis,et al.  A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer , 2009, Cell cycle.

[5]  A. Magis,et al.  A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. , 2008, Journal of medicinal chemistry.

[6]  Matthew D. Wessel,et al.  Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. , 2008, Cancer research.

[7]  V. Golubovskaya,et al.  TAE226‐Induced apoptosis in breast cancer cells with overexpressed Src or EGFR , 2008, Molecular carcinogenesis.

[8]  Liz Y. Han,et al.  Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. , 2007, Cancer research.

[9]  Xinming Cai,et al.  Structural Basis for the Autoinhibition of Focal Adhesion Kinase , 2007, Cell.

[10]  Christopher Autry,et al.  Cellular Characterization of a Novel Focal Adhesion Kinase Inhibitor* , 2007, Journal of Biological Chemistry.

[11]  W. Yung,et al.  Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo , 2007, Molecular Cancer Therapeutics.

[12]  V. Golubovskaya,et al.  Focal adhesion kinase and p53 signaling in cancer cells. , 2007, International review of cytology.

[13]  Bob van de Water,et al.  Focal adhesion kinase: a potential target in cancer therapy. , 2007, Biochemical pharmacology.

[14]  Neil O. Carragher,et al.  The role of focal-adhesion kinase in cancer — a new therapeutic opportunity , 2005, Nature Reviews Cancer.

[15]  Xianyue Ma,et al.  Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of Jak2 tyrosine kinase autophophorylation , 2005 .

[16]  Xianyue Ma,et al.  Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation]. , 2005, Journal of medicinal chemistry.

[17]  Y. L. Chen,et al.  [Focal adhesion kinase]. , 1999, Sheng li ke xue jin zhan [Progress in physiology].

[18]  D. Schlaepfer,et al.  Signaling through focal adhesion kinase. , 1999, Progress in biophysics and molecular biology.

[19]  S. J. Taylor,et al.  Direct interaction of v-Src with the focal adhesion kinase mediated by the Src SH2 domain. , 1994, Molecular biology of the cell.

[20]  J. Parsons,et al.  Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src , 1994, Molecular and cellular biology.

[21]  J. Parsons,et al.  Stable association of pp60src and pp59fyn with the focal adhesion-associated protein tyrosine kinase, pp125FAK , 1994, Molecular and cellular biology.

[22]  J. Parsons,et al.  Identification of sequences required for the efficient localization of the focal adhesion kinase, pp125FAK, to cellular focal adhesions , 1993, The Journal of cell biology.